Practice in the Radiation Therapy for Stage D1 Prostate Cancer: Survey of the Japanese Radiation Oncology Study Group (JROSG)
Not Applicable
- Conditions
- Radiation therapy for stage D1 prostate cancer
- Registration Number
- JPRN-UMIN000035990
- Lead Sponsor
- ihon University school of medicine
- Brief Summary
The median follow-up period was 53 months (range, 9-99). Estimated 5-year overall and progression free survival rates were 84.6% and 69.3%, respectively. Fifty-one (30.2%) patients developed biochemical recurrence.Multivariate analyses indicated that BED was the only significant prognostic factor for overall survival (p=0.01) and DSS (p=0.04).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Male
- Target Recruitment
- 169
Inclusion Criteria
Not provided
Exclusion Criteria
There is no pathological diagnosis Patients undergoing surgery for prostate cancer
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Overall Survical
- Secondary Outcome Measures
Name Time Method Progression-free survival, disease-free survival, adverse events rate